Barclays’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.8M | Sell |
289,874
-552,997
| -66% | -$43.6M | 0.01% | 1059 |
|
|
2025
Q4 | $66.7M | Buy |
842,871
+128,823
| +18% | +$9.7M | 0.02% | 646 |
|
|
2025
Q3 | $46.7M | Buy |
714,048
+130,782
| +22% | +$6.39M | 0.01% | 807 |
|
|
2025
Q2 | $23M | Buy |
583,266
+229,329
| +65% | +$7.5M | 0.01% | 1056 |
|
|
2025
Q1 | $10.7M | Sell |
353,937
-242,135
| -41% | -$7.93M | ﹤0.01% | 1359 |
|
|
2024
Q4 | $20.8M | Sell |
596,072
-40,960
| -6% | -$1.53M | 0.01% | 1101 |
|
|
2024
Q3 | $25.5M | Buy |
637,032
+21,358
| +3% | +$994K | 0.01% | 946 |
|
|
2024
Q2 | $29.3M | Buy |
615,674
+38,287
| +7% | +$1.57M | 0.01% | 807 |
|
|
2024
Q1 | $25M | Sell |
577,387
-67,121
| -10% | -$3.2M | 0.01% | 890 |
|
|
2023
Q4 | $32.6M | Buy |
644,508
+4,955
| +0.8% | +$237K | 0.01% | 858 |
|
|
2023
Q3 | $29M | Buy |
639,553
+97,321
| +18% | +$4.02M | 0.02% | 656 |
|
|
2023
Q2 | $22.2M | Buy |
542,232
+83,415
| +18% | +$3.21M | 0.01% | 687 |
|
|
2023
Q1 | $16.4M | Sell |
458,817
-48,494
| -10% | -$1.82M | 0.01% | 935 |
|
|
2022
Q4 | $19.2M | Buy |
507,311
+2,823
| +0.6% | +$119K | 0.01% | 914 |
|
|
2022
Q3 | $22.3M | Buy |
504,488
+149,909
| +42% | +$6.32M | 0.02% | 571 |
|
|
2022
Q2 | $13.1M | Buy |
354,579
+38,229
| +12% | +$1.44M | 0.01% | 900 |
|
|
2022
Q1 | $11.7M | Sell |
316,350
-13,588
| -4% | -$445K | 0.01% | 858 |
|
|
2021
Q4 | $10M | Sell |
329,938
-353
| -0.1% | -$11.1K | ﹤0.01% | 1267 |
|
|
2021
Q3 | $11.1M | Sell |
330,291
-33,705
| -9% | -$1.27M | 0.01% | 1147 |
|
|
2021
Q2 | $14.5M | Buy |
363,996
+265,225
| +269% | +$10.4M | 0.01% | 1035 |
|
|
2021
Q1 | $4.44M | Buy |
98,771
+29,106
| +42% | +$1.62M | ﹤0.01% | 1616 |
|
|
2020
Q4 | $3.94M | Sell |
69,665
-6,182
| -8% | -$308K | ﹤0.01% | 1686 |
|
|
2020
Q3 | $3.6M | Sell |
75,847
-3,954
| -5% | -$220K | ﹤0.01% | 1632 |
|
|
2020
Q2 | $4.71M | Buy |
79,801
+16,979
| +27% | +$945K | ﹤0.01% | 1420 |
|
|
2020
Q1 | $2.97M | Sell |
62,822
-32,258
| -34% | -$1.8M | ﹤0.01% | 1916 |
|
|
2019
Q4 | $5.74M | Buy |
95,080
+40,921
| +76% | +$2.44M | ﹤0.01% | 1862 |
|
|
2019
Q3 | $3.24M | Sell |
54,159
-204,634
| -79% | -$13.3M | ﹤0.01% | 2299 |
|
|
2019
Q2 | $16.6M | Buy |
258,793
+140,885
| +119% | +$9.96M | 0.01% | 1033 |
|
|
2019
Q1 | $9.57M | Buy |
117,908
+55,351
| +88% | +$3.57M | 0.01% | 1253 |
|
|
2018
Q4 | $3.38M | Sell |
62,557
-12,479
| -17% | -$636K | ﹤0.01% | 1900 |
|
|
2018
Q3 | $3.87M | Buy |
75,036
+61,681
| +462% | +$2.9M | ﹤0.01% | 2086 |
|
|
2018
Q2 | $556K | Sell |
13,355
-51,490
| -79% | -$2.28M | ﹤0.01% | 3841 |
|
|
2018
Q1 | $2.86M | Buy |
64,845
+51,577
| +389% | +$2.62M | ﹤0.01% | 2118 |
|
|
2017
Q4 | $667K | Sell |
13,268
-29,739
| -69% | -$1.63M | ﹤0.01% | 3527 |
|
|
2017
Q3 | $2.18M | Buy |
43,007
+30,256
| +237% | +$1.58M | ﹤0.01% | 2254 |
|
|
2017
Q2 | $649K | Sell |
12,751
-61,439
| -83% | -$2.86M | ﹤0.01% | 3265 |
|
|
2017
Q1 | $2.98M | Buy |
74,190
+28,562
| +63% | +$1.28M | ﹤0.01% | 1716 |
|
|
2016
Q4 | $2.18M | Buy |
45,628
+11,077
| +32% | +$438K | ﹤0.01% | 2048 |
|
|
2016
Q3 | $1.26M | Sell |
34,551
-106,115
| -75% | -$3.32M | ﹤0.01% | 2406 |
|
|
2016
Q2 | $3.28M | Buy |
140,666
+78,330
| +126% | +$2.53M | ﹤0.01% | 1614 |
|
|
2016
Q1 | $2.49M | Sell |
62,336
-6,659
| -10% | -$270K | ﹤0.01% | 1729 |
|
|
2015
Q4 | $4.21M | Sell |
68,995
-29,766
| -30% | -$1.61M | 0.01% | 1444 |
|
|
2015
Q3 | $3.95M | Buy |
98,761
+17,820
| +22% | +$922K | ﹤0.01% | 1528 |
|
|
2015
Q2 | $4.62M | Sell |
80,941
-21,998
| -21% | -$1.4M | 0.01% | 1549 |
|
|
2015
Q1 | $6.49M | Buy |
102,939
+22,265
| +28% | +$1.51M | 0.01% | 1364 |
|
|
2014
Q4 | $4.92M | Sell |
80,674
-33,278
| -29% | -$1.64M | ﹤0.01% | 1718 |
|
|
2014
Q3 | $4.33M | Sell |
113,952
-65,505
| -37% | -$2.32M | ﹤0.01% | 1916 |
|
|
2014
Q2 | $6.1M | Buy |
179,457
+81,525
| +83% | +$2.57M | 0.01% | 1557 |
|
|
2014
Q1 | $4.21M | Buy |
97,932
+2,991
| +3% | +$145K | ﹤0.01% | 1843 |
|
|
2013
Q4 | $3.7M | Buy |
94,941
+38,869
| +69% | +$1.38M | ﹤0.01% | 2068 |
|
|
2013
Q3 | $2.08M | Buy |
56,072
+21,400
| +62% | +$639K | ﹤0.01% | 2532 |
|
|
2013
Q2 | $931K | Buy |
+34,672
| New | +$737K | ﹤0.01% | 3467 |
|
Other funds holding IONS
VPM
VCM
Barclays's IONS Position: Q1 2026 in Review
Barclays reduced its Ionis Pharmaceuticals (IONS) stake by 66% in Q1 2026, selling an estimated $43.6M and leaving 289,874 shares worth $21.8M. The position accounts for 0.01% of the portfolio, ranked #1059.
Barclays first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $66.7M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Barclays held 289,874 shares of Ionis Pharmaceuticals worth $21.8M as of Q1 2026.
- Barclays sold 552,997 Ionis Pharmaceuticals shares in Q1 2026, an estimated $43.6M.
- Ionis Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #1059 holding.
- Barclays first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Ionis Pharmaceuticals position peaked at $66.7M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.